Janssen announced positive results of its PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial that compared schizophrenia medications.
PRIDE was a 15-month multicenter, prospective, randomized, open-label, event monitoring board-blinded, active-controlled study that assessed 444 adults diagnosed with schizophrenia and had been taken into custody by the criminal justice system at least twice in the previous 2 years, with at least one custody resulting in incarceration. Patients were randomized to either once-monthly Invega Sustenna (78–234mg) or to one of 7 commonly prescribed antipsychotics: aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine and risperidone. The primary endpoint was time to treatment failure, a subset of relapse.
Results showed that once-monthly Invega Sustenna (paliperidone palmitate extended-release) significantly delayed time to relapse, as well as reduced overall relapse vs. commonly used treatments. Invega Sustenna showed statistical superiority against the primary endpoint, delaying relapse in patients with schizophrenia, as well as in reducing overall relapse, compared to the most commonly used treatments, daily oral antipsychotics (median 416 days vs. median 226 days; P=0.011). The risk of relapse was 1.4 times higher (95% CI: 1.09, 1.88; P=0.011) in the oral group vs. the Invega Sustenna group.
For more information call (800) 526-7736 or visit InvegaSustenna.com.